IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced the launch of IMS Aggregate Spend Compliance Services, a comprehensive set of solutions to help pharmaceutical and medical device companies comply with the growing number of federal and state transparency and marketing disclosure laws in the U.S., known as “aggregate spend” reporting regulations…

See the original post:
IMS Launches Integrated Regulatory Compliance Solution For Pharmaceutical And Medical Device Companies

You may also like:

• Anulex Technologies, Inc. Announces The Launch Of The Xclose™ Plus Tissue Repair System And Achieves 7,300 Patients Treated Milestone
• Novartis Hosts Scientific Symposium In Philippines To Review Research Approaches, Clinical Management, And Growing Presence Of Dengue
• Fifteen Approved Active Pharmaceutical Ingredients Added To Pharmaceutical Substances Version 3.2
• Catalyst Pharmaceutical Partners Announces Top-Line Results Of CPP-109 Phase II Trial For Cocaine Addiction
• Boston Scientific Welcomes Launch Of Syntax Score Website
• HHS Requires Bidders In Competitive Range For Recombinant Anthrax Vaccine (rPA) Contract To Submit Development Plan To FDA For Review
• Dental Treatment Tools For Those Dying To Spend Less Quality Time With Their Dentists? There’s An App For That
• Somaxon Pharmaceuticals Announces Acceptance Of Phase 3 Clinical Trial Data For Publication In Sleep And Sleep Medicine
• Loyola Wins Gold Plus Award For Stroke Care For Second Year In A Row
• New QUM Kit On Pain Management Available From PSA, Australia